Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 164

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 164
---
5% CER, at € 8,299 million. Sales reflected a strong Beyfortus ramp-up, which more than offset the absence of COVID-19 vaccine sales in the period (versus € 226 million in 2023). Sales of Polio/Pertussis/Hib Vaccines and Boosters , reached € 2,741 million, up 1.2% CER. Growth was driven by increased demand for Booster vaccines across all regions, and continued expansion of our pediatric combination vaccines in the Rest of World region. In the United States, Vaxelis became market leader in the three-dose primary series market for infants at the end of 2023. Vaxelis sales in the United States are not consolidated by Sanofi, but profits are shared equally between Sanofi and Merck & Co. Sales of Influenza Vaccines reached € 2,555 million, down 1.3% CER, due to soft vaccination coverage. Beyfortus sales reached € 1,686 million, driven by a successful rollout in the first full year of launch. In collaboration with AstraZeneca, who manufacture Beyfortus, increased supply was enabled by additional capacity. Meningitis, Travel and Endemics Vaccines sales increased by 5.4% CER to € 1,316 million, reflecting the expansion of MenQuadfi in Europe and the Rest of the World region. 4/ Net sales by geographical region The table below sets forth our net sales for 2024 and 2023 by geographical region:

| (€ million)       |   2024 |   2023 | Change ona reported basis | Change at constantexchange rates |
| United States     | 19,986 | 17,262 | +15.8%                    | +16.2%                           |
| Europe            |  9,027 |  8,816 | +2.4%                     | +2.3%                            |
| Rest of the World | 12,068 | 11,739 | +2.8%                     | +10.7%                           |
| of which China    |  2,666 |  2,728 | -2.3%                     | -0.5%                            |
| Total net sales   | 41,081 | 37,817 | +8.6%                     | +11.3%                           |

In 2024 , net sales in the United